Sodium butyrate induces neuroendocrine cytodifferentiation in the insulinoma cell line RINm5F.
The differentiating agent sodium butyrate inhibits proliferation and stimulates cell-specific hormone expression in rat insulinoma cells. In this study, we investigated the effect of sodium butyrate on neuroendocrine cytodifferentiation in the rat insulinoma subclone, RINm5F. The cells were cultured with 0.5, 1, or 1.5 mM sodium butyrate for up to 72 h. Ultrastructurally, cells cultured with 1 mM sodium butyrate revealed a more differentiated appearance with an induction of cellular compartments involved in regulated insulin secretion. Morphometric analysis showed a significant elevation of neuroendocrine granule density. The total area of the specific granules was increased after incubation with 1 mM sodium butyrate for 48 and 72 h. Proliferation of RINm5F cells was inhibited by sodium butyrate in a dose-dependent manner. DNA production ceased completely within 24 h at 1.5 mM sodium butyrate. This concentration of sodium butyrate increased the cellular insulin content 8.9-fold and the insulin production 2-fold after 72 h. The insulin release was reduced from 79 +/- 3.5% in controls to 37 +/- 5.6% of total in a 24-h incubation period after 3 days of culture with 1.5 mM sodium butyrate. Insulin mRNA levels increased to a maximum of 324% compared with controls after 48 h of culture with 1.5 mM sodium butyrate. Chromogranin A mRNA levels increased to a similar extent (368 +/- 26%), whereas sodium butyrate did not stimulate the expression of synaptophysin, a major membrane component of small neuroendocrine vesicles. In conclusion, our data suggest the selective induction of neuroendocrine cytodifferentiation by sodium butyrate in RINm5F cells.(ABSTRACT TRUNCATED AT 250 WORDS)
Swarovsky
B
B
Department of Internal Medicine, Gastroenterology, and Metabolism, Philipps-University, Marburg, Germany.
Eissele
R
R
Eisenacher
M
M
Trautmann
M E
ME
Arnold
R
R
D015152:Blotting, Northern; D002087:Butyrates / Q000494:pharmacology*; D020148:Butyric Acid; D002454:Cell Differentiation; D053379:Chromogranin A; D002864:Chromogranins / Q000235:genetics; D003594:Cytoplasmic Granules / Q000187:drug effects / Q000648:ultrastructure; D004273:DNA, Neoplasm / Q000032:analysis / Q000096:biosynthesis; D015870:Gene Expression; D006801:Humans; D007328:Insulin / Q000032:analysis* / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism; D000078790:Insulin Secretion; D007340:Insulinoma / Q000235:genetics / Q000378:metabolism / Q000648:ultrastructure*; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure; D008565:Membrane Proteins / Q000235:genetics; D008854:Microscopy, Electron; D009490:Neurosecretory Systems / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D009693:Nucleic Acid Hybridization; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000378:metabolism / Q000648:ultrastructure*; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D012334:RNA, Neoplasm / Q000032:analysis / Q000235:genetics; D016708:Synaptophysin / Q000235:genetics; D014407:Tumor Cells, Cultured
D002087:Butyrates; D053379:Chromogranin A; D002864:Chromogranins; D004273:DNA, Neoplasm; D007328:Insulin; D008565:Membrane Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D016708:Synaptophysin; D020148:Butyric Acid